JP2012508178A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012508178A5 JP2012508178A5 JP2011534915A JP2011534915A JP2012508178A5 JP 2012508178 A5 JP2012508178 A5 JP 2012508178A5 JP 2011534915 A JP2011534915 A JP 2011534915A JP 2011534915 A JP2011534915 A JP 2011534915A JP 2012508178 A5 JP2012508178 A5 JP 2012508178A5
- Authority
- JP
- Japan
- Prior art keywords
- nilotinib hcl
- degrees
- crystalline
- powder
- ray diffraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- VTGGYCCJUPYZSX-UHFFFAOYSA-N 4-methyl-n-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide;hydrochloride Chemical compound Cl.C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 VTGGYCCJUPYZSX-UHFFFAOYSA-N 0.000 claims description 90
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 28
- 239000000126 substance Substances 0.000 claims description 20
- 239000002002 slurry Substances 0.000 claims description 12
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 claims description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000005536 L01XE08 - Nilotinib Substances 0.000 claims description 5
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims description 5
- 229960001346 nilotinib Drugs 0.000 claims description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 2
- 229940011051 isopropyl acetate Drugs 0.000 claims description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 239000013078 crystal Substances 0.000 description 6
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 5
- 238000001816 cooling Methods 0.000 description 3
- 239000012453 solvate Substances 0.000 description 1
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11156108P | 2008-11-05 | 2008-11-05 | |
| US61/111,561 | 2008-11-05 | ||
| US15578909P | 2009-02-26 | 2009-02-26 | |
| US61/155,789 | 2009-02-26 | ||
| US17745409P | 2009-05-12 | 2009-05-12 | |
| US61/177,454 | 2009-05-12 | ||
| US22721009P | 2009-07-21 | 2009-07-21 | |
| US61/227,210 | 2009-07-21 | ||
| US24070909P | 2009-09-09 | 2009-09-09 | |
| US61/240,709 | 2009-09-09 | ||
| US24251409P | 2009-09-15 | 2009-09-15 | |
| US61/242,514 | 2009-09-15 | ||
| US24679909P | 2009-09-29 | 2009-09-29 | |
| US61/246,799 | 2009-09-29 | ||
| US24937609P | 2009-10-07 | 2009-10-07 | |
| US61/249,376 | 2009-10-07 | ||
| PCT/US2009/063365 WO2010054056A2 (en) | 2008-11-05 | 2009-11-05 | Nilotinib hci crystalline forms |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012508178A JP2012508178A (ja) | 2012-04-05 |
| JP2012508178A5 true JP2012508178A5 (enExample) | 2012-12-20 |
| JP5486012B2 JP5486012B2 (ja) | 2014-05-07 |
Family
ID=41666779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011534915A Active JP5486012B2 (ja) | 2008-11-05 | 2009-11-05 | ニロチニブＨＣｌ結晶形 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US8227477B2 (enExample) |
| EP (2) | EP2530081A3 (enExample) |
| JP (1) | JP5486012B2 (enExample) |
| KR (2) | KR20120111743A (enExample) |
| CN (1) | CN102203084B (enExample) |
| CA (1) | CA2740794A1 (enExample) |
| DK (1) | DK2262793T3 (enExample) |
| ES (1) | ES2394258T3 (enExample) |
| HR (1) | HRP20120793T1 (enExample) |
| PL (1) | PL2262793T3 (enExample) |
| TW (1) | TW201022240A (enExample) |
| WO (1) | WO2010054056A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2010KO00035A (enExample) * | 2010-01-15 | 2016-09-02 | ||
| WO2011133675A1 (en) * | 2010-04-21 | 2011-10-27 | Teva Pharmaceutical Industries Ltd. | Gabapentin enacarbil compositions |
| US8937082B2 (en) | 2010-06-21 | 2015-01-20 | Teva Pharmaceutical Industries Ltd. | Nilotinib salts and crystalline forms thereof |
| CN103038227A (zh) * | 2010-06-21 | 2013-04-10 | 特瓦制药工业有限公司 | 尼洛替尼盐及其晶形 |
| CN102453024B (zh) * | 2010-10-27 | 2014-09-03 | 浙江九洲药业股份有限公司 | 一种尼罗替尼盐酸盐晶型及其制备方法 |
| WO2012070062A2 (en) * | 2010-11-26 | 2012-05-31 | Hetero Research Foundation | Novel polymorph of nilotinib hydrochloride |
| WO2012164578A1 (en) * | 2011-06-02 | 2012-12-06 | Hetero Research Foundation | Compositions and methods for preparing immediate release formulations of nilotinib |
| AR086913A1 (es) * | 2011-06-14 | 2014-01-29 | Novartis Ag | 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas |
| EP2626355B1 (en) * | 2012-02-09 | 2016-02-03 | Natco Pharma Limited | Process for the preparation of nilotinib hydrochloride |
| US9061028B2 (en) | 2012-02-15 | 2015-06-23 | Natco Pharma Limited | Process for the preparation of Nilotinib |
| CA2888002A1 (en) * | 2012-10-15 | 2014-04-24 | Apotex Inc. | Solid forms of nilotinib hydrochloride |
| JP2015534967A (ja) * | 2012-10-19 | 2015-12-07 | ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ | ニロチニブと選択された共結晶体を含有する多成分結晶系 |
| US9580408B2 (en) * | 2013-04-24 | 2017-02-28 | Dr. Reddy's Laboratories Limited | Polymorphic forms of nilotinib hydrochloride |
| US9636340B2 (en) | 2013-11-12 | 2017-05-02 | Ayyappan K. Rajasekaran | Kinase inhibitors |
| WO2015092624A1 (en) | 2013-12-16 | 2015-06-25 | Ranbaxy Laboratories Limited | Nilotinib mono-oxalate and its crystalline form |
| EP3177610A4 (en) | 2014-08-08 | 2018-01-10 | Dr. Reddy's Laboratories Ltd. | Process for the preparation of polymorphic forms of nilotinib |
| US10016423B2 (en) | 2014-10-16 | 2018-07-10 | Apotex Inc. | Solid forms of nilotinib hydrochloride |
| CN106478603B (zh) * | 2015-08-25 | 2021-01-01 | 江苏豪森药业集团有限公司 | 尼洛替尼盐酸盐的新晶型及其制备方法和医药用途 |
| EA036204B1 (ru) * | 2015-10-16 | 2020-10-14 | Нобел Илач Санайи Ве Тиджарет А.Ш. | Фармацевтические композиции нилотиниба гидрохлорида |
| WO2017129694A1 (en) | 2016-01-26 | 2017-08-03 | Farma Grs, D.O.O. | Nilotinib dinitrate (v) and crystalline forms thereof |
| SI3430004T1 (sl) | 2016-03-14 | 2021-03-31 | Pliva Hrvatska D.O.O. | Trdne oblike soli nilotiniba |
| EP3404025B1 (en) | 2017-05-16 | 2019-12-04 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Process for the preparation of pure nilotinib and its salt |
| CZ2017821A3 (cs) | 2017-12-20 | 2019-07-03 | Zentiva, K.S. | Léková forma obsahující krystalický nilotinib |
| KR20210042896A (ko) | 2018-06-15 | 2021-04-20 | 한다 파마슈티칼스, 인코포레이티드 | 카이네이스 억제제 염 및 이의 조성물 |
| WO2020095187A1 (en) * | 2018-11-05 | 2020-05-14 | Laurus Labs Limited | Crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical composition containing the same |
| US20240316044A1 (en) | 2021-06-19 | 2024-09-26 | Helm Ag | Granulate composition comprising nilotinib |
| EP4122452A1 (en) | 2021-07-23 | 2023-01-25 | KRKA, d.d., Novo mesto | Pharmaceutical composition comprising nilotinib and method of manufacturing the same |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0215676D0 (en) * | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| GB0325031D0 (en) | 2003-10-27 | 2003-12-03 | Novartis Ag | Organic compounds |
| MY146795A (en) | 2005-06-09 | 2012-09-28 | Novartis Ag | Process for the synthesis of organic compounds |
| SA06270147B1 (ar) | 2005-06-09 | 2009-12-22 | نوفارتيس ايه جي | عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين |
| CN101228150B (zh) * | 2005-07-20 | 2014-10-15 | 诺华股份有限公司 | 4-甲基-n-[3-(4-甲基-咪唑-1-基)-5-三氟甲基-苯基]-3-(4-吡啶-3-基-嘧啶-2-基氨基)-苯甲酰胺的晶形 |
| GT200600315A (es) | 2005-07-20 | 2007-03-19 | Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida | |
| GT200600316A (es) * | 2005-07-20 | 2007-04-02 | Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida. | |
| FR2889524B1 (fr) | 2005-08-05 | 2008-08-29 | Rhodia Chimie Sas | Procede de formation d'une liaison carbone-azote |
| KR100674813B1 (ko) | 2005-08-05 | 2007-01-29 | 일양약품주식회사 | Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법 |
| WO2010009402A2 (en) * | 2008-07-17 | 2010-01-21 | Teva Pharmaceutical Industries Ltd. | Nilotinib intermediates and preparation thereof |
-
2009
- 2009-11-05 EP EP12182091.4A patent/EP2530081A3/en not_active Withdrawn
- 2009-11-05 CA CA2740794A patent/CA2740794A1/en not_active Abandoned
- 2009-11-05 PL PL09752057T patent/PL2262793T3/pl unknown
- 2009-11-05 ES ES09752057T patent/ES2394258T3/es active Active
- 2009-11-05 CN CN200980144606.XA patent/CN102203084B/zh active Active
- 2009-11-05 US US12/612,943 patent/US8227477B2/en active Active
- 2009-11-05 TW TW098137645A patent/TW201022240A/zh unknown
- 2009-11-05 KR KR1020127021115A patent/KR20120111743A/ko not_active Ceased
- 2009-11-05 WO PCT/US2009/063365 patent/WO2010054056A2/en not_active Ceased
- 2009-11-05 HR HRP20120793AT patent/HRP20120793T1/hr unknown
- 2009-11-05 KR KR1020107014884A patent/KR101251726B1/ko active Active
- 2009-11-05 JP JP2011534915A patent/JP5486012B2/ja active Active
- 2009-11-05 EP EP09752057A patent/EP2262793B1/en not_active Revoked
- 2009-11-05 DK DK09752057.1T patent/DK2262793T3/da active
-
2012
- 2012-06-27 US US13/535,105 patent/US8592442B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012508178A5 (enExample) | ||
| JP2010516681A5 (enExample) | ||
| RU2466129C2 (ru) | Твердые формы рацемического илапразола | |
| JP2009235086A5 (enExample) | ||
| JP2015010091A5 (enExample) | ||
| JP6447508B2 (ja) | ３−（イミダゾ［１，２−ｂ］ピリダジン−３−イルエチニル）−４−メチル−Ｎ−｛４−［（４−メチルピペラジン−１−イル）メチル］−３−（トリフルオロメチル）フェニル｝ベンズアミドおよびその一塩酸塩の結晶形 | |
| JP2007532560A5 (enExample) | ||
| CN1227233C (zh) | 纯晶形的5－氯－3－(4－甲磺酰基苯基)－6′－甲基－[2,3′]联吡啶及其合成方法 | |
| JP2014526498A5 (enExample) | ||
| JP2012176975A5 (enExample) | ||
| ES2614934T3 (es) | Nueva forma cristalina III de agomelatina, su procedimiento de preparación y composiciones farmacéuticas que la contienen | |
| JP2009514988A5 (enExample) | ||
| JP5303765B2 (ja) | 結晶性イミダゾール−５−カルボン酸誘導体 | |
| KR20220007650A (ko) | N-(5-(5-((1r,2s)-2-플루오로시클로프로필)-1,2,4-옥사디아졸-3-일)-2-메틸페닐)이미다조[1,2-a]피리딘-3-카르복스아미드의 결정질 형태 | |
| JP2015516425A5 (enExample) | ||
| JP2016510767A5 (enExample) | ||
| JP2016512518A (ja) | ベムラフェニブ塩酸塩の固体形態 | |
| JP2012530118A5 (enExample) | ||
| JP2015531354A5 (enExample) | ||
| JP2010540440A5 (enExample) | ||
| JP2020524707A (ja) | 塩酸メフパリブの多形体およびその製造方法と使用 | |
| JP2013224245A (ja) | ＢａＴｉ２Ｏ５系複合酸化物の製造方法 | |
| JP6307634B2 (ja) | アリサルタン・イソプロキシル結晶、その製造方法及び該結晶を含む医薬組成物 | |
| JP2016535767A (ja) | アリサルタン・イソプロキシル非晶形とその調製方法及びその非晶形を含む医薬組成物 | |
| JP5827684B2 (ja) | ２−［３−シアノ−４−（２−ｉ−ブトキシ）フェニル］−４−メチル−５−チアゾール−カルボン酸（フェブキソスタット）の結晶形Ａを調製するための方法 |